title: mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
authors.affiliation: Department of Urology, Lukas Hospital, Preussen Strasse 84, Neuss, Germany. CEimer@lukasneuss.de
authors.forename: Christoph
authors.initials: C
authors.lastname: Eimer
authors.forename: Holger
authors.initials: H
authors.lastname: Gerullis
authors.forename: Christoph
authors.initials: C
authors.lastname: Heuck
authors.forename: Thomas
authors.initials: T
authors.lastname: Otto
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases